Showing 7881-7890 of 9428 results for "".
- PellePharm Presents New Data in BCChttps://practicaldermatology.com/news/pellepharm-presents-new-data-in-bcc/2457731/PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs at the International Investigative Dermatology (IID) Meeting in Orlando, FL. The data, presented i
- New CFO at Evolus, Inc.https://practicaldermatology.com/news/new-cfo-at-evolus-inc/2457744/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- Psoriatic Arthritis Awareness Project Launcheshttps://practicaldermatology.com/news/psoriatic-arthritis-awareness-project-launches/2457751/In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awareness Project. The PsA Awareness Project is a set of patient films that highlight the impo
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID)
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- Industry Vet James P. Hartman Named New Chief Commercial Officer at Alastinhttps://practicaldermatology.com/news/industry-vet-james-p-hartman-named-new-chief-commercial-officer-at-alastin/2457772/James P. Hartman is the new Chief Commercial Officer of Alastin Skincare, Inc.— effective May 14, 2018. Mr. Hartman recently served as Vice President & General Manager at Solta Medical, a division of Valeant Pharmaceuticals. Prior to Sol
- Daily Aspirin Linked to Higher Melanoma Risk in Menhttps://practicaldermatology.com/news/daily-aspirin-linked-to-higher-melanoma-risk-in-men/2457779/Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who don’t, reports a new Northwestern Medicine study. Women, however, do not have an increased risk in this large patient population, the study showed. The study collected medical record
- Encore Dermatology Launches Impoyz Cream 0.025%, a Newly Formulated High-Potency Topical Corticosteroidhttps://practicaldermatology.com/news/encore-dermatology-launches-impoyz-cream-0025-a-newly-formulated-high-potency-topical-corticosteroid/2457787/Encore Dermatology Inc. launched its new topical product, Impoyz Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate. &ld
- Hair Products for Black Women May Contain Mix of Hazardous Ingredientshttps://practicaldermatology.com/news/hair-products-for-black-women-may-contain-mix-of-hazardous-ingredients/2457790/Black women are potentially exposed to dozens of hazardous chemicals through their hair products, finds a new report in the journal Environmental Research. The study, led by scientists at Silent Spr